UNITY Biotechnology, Inc. to Announce First Quarter 2019 Financial Results April 29, 2019 at 4:05 PM EDT PDF Version SAN FRANCISCO, April 29, 2019 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, plans to report results for the second quarter ended March 31, 2019, on Wednesday, May 8, 2019, after NASDAQ market close. UNITY will not conduct a conference call in conjunction with the financial results press release. About UNITY UNITY is developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging. UNITY's initial focus is on creating senolytic medicines to selectively eliminate senescent cells and thereby treat age-related diseases, such as osteoarthritis, eye diseases and pulmonary diseases. More information is available at www.unitybiotechnology.com or follow us on Twitter. Investors Peter Rahmerprahmer@enduranceadvisors.com Media Canale CommunicationsJason Spark 1-619-849-6005 firstname.lastname@example.org Source: Unity Biotechnology, Inc.